用于治疗HIV-1相关神经认知障碍的血小板活化因子拮抗剂的研发。
Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders.
作者信息
Eggert Dawn, Dash Prasanta K, Serradji Nawal, Dong Chang-Zhi, Clayette Pascal, Heymans Francoise, Dou Huanyu, Gorantla Santhi, Gelbard Harris A, Poluektova Larisa, Gendelman Howard E
机构信息
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198-5880, USA.
出版信息
J Neuroimmunol. 2009 Aug 18;213(1-2):47-59. doi: 10.1016/j.jneuroim.2009.06.002. Epub 2009 Jun 21.
The neuroregulatory activities of PMS-601, a platelet activating factor antagonist, were investigated in laboratory and animal models of HIV-1 encephalitis (HIVE). For the former, PMS-601 reduced monocyte-derived macrophage pro-inflammatory secretions, multinucleated giant cell (MGC) formation, and neuronal loss independent of antiretroviral responses. PMS-601 treatment of HIVE severe combined immunodeficient mice showed reduced microgliosis, MGCs and neurodegeneration. These observations support the further development of PMS-601 as an adjunctive therapy for HIV-1 associated neurocognitive disorders.
血小板活化因子拮抗剂PMS-601的神经调节活性在HIV-1脑炎（HIVE）的实验室和动物模型中进行了研究。对于前者，PMS-601可减少单核细胞衍生的巨噬细胞促炎分泌物、多核巨细胞（MGC）形成和神经元损失，且与抗逆转录病毒反应无关。PMS-601治疗HIVE严重联合免疫缺陷小鼠可减少小胶质细胞增生、MGC和神经变性。这些观察结果支持将PMS-601进一步开发为HIV-1相关神经认知障碍的辅助治疗方法。
Zotero 插件